| Nov 20 |
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
|
| Nov 20 |
GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment
|
| Nov 20 |
Grifols Signals It Would Reject $6.8 Billion Brookfield Bid
|
| Nov 19 |
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update)
|
| Nov 19 |
Grifols: Brookfield's potential $6.8 billion offer undervalues the firm
|
| Nov 19 |
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus
|
| Nov 19 |
Brookfield Weighs €6.45 Billion Bid for Grifols; Shares Drop
|
| Nov 18 |
Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols
|
| Nov 8 |
Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ...
|
| Nov 8 |
Grifols holder Mason Capital against potential Brookfield deal
|
